Kite Pharma (KITE) Will Present KTE-C19 Data in PMBCL, TFL at ASH 2016
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/23/2024
- Wall St gains on bright earnings, megacaps' support
- JPMorgan is worried about further S&P 500 sell-off potential
- Oil falls back after robust EU data as Mideast tensions linger
- China acquired top-end Nvidia AI chips despite recent US ban- Reuters
- SAP Q1 results fall short of Wall Street estimates as transformation kicks off
- Fisker (FSR) Appoints Michael Healy as Chief Restructuring Officer
- Kroger (KR), Albertsons and C&S Wholesale Grocers Announce an Updated and Expanded Divestiture Plan
- Costar Group (CSGP) to Acquire Matterport (MTTR) for $5.50/sh Cash and Stock
- Jaguar Health (JAGX) Files $75M Mixed Shelf
- Apple (AAPL) PT Lowered to $210 at Morgan Stanley, 'We'd buy post-earnings weakness'
- Apple, PepsiCo, JetBlue fall premarket; Amazon, GM and UPS rise
- After-hours movers: Cadence Design Systems, Cleveland-Cliffs, Riot Platforms, and more
- Midday movers: Tesla, Li Auto and CNH Industrial fall; Salesforce rises
- Midday movers: Netflix, Super Micro fall; Paramount Global gains
- After-hours movers: Netflix, Intuitive Surgical, Nordstrom, KB Home
Kite Pharma to Present KTE-C19 Data from Interim Analysis of the ZUMA-1 Pivotal Trial in Patients with Chemorefractory Primary Mediastinal B-Cell Lymphoma (PMBCL) and Transformed Follicular Lymphoma (
November 3, 2016 9:28 AM EDTOral Presentation on Novel T cell Manufacturing Process for KTE-C19 in Acute Lymphoblastic Leukemia (ALL) Poster Presentation of Preliminary Safety and Efficacy Data from the Phase 1 Portion of ZUMA-3 and ZUMA-4 Trials in Adult and Pediatric Patients with Relapsed/Refractory (R/R) ALL Oral Presentation of Clinical Data from First Fully Human Anti-CD19 Chimeric Antigen Receptor (huCAR-19) Investigational Cell Therapy to Enter Clinical Study
SANTA MONICA, Calif.--(BUSINESS WIRE)-- Kite Pharma, Inc.... More
